# PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Source: https://onco.cc/trials/nct05801237/  
OnCo record `nct05801237` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PE0116&PE0105 in advanced solid tumours, run by Shanghai HyaMab Biotech Co.,Ltd., now recruiting.

## Summary

PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT05801237 by Shanghai HyaMab Biotech Co.,Ltd., with 120 participants planned, started 2023-09-21 and due to reach its primary completion in 2026-09. Interventions recorded: PE0116&PE0105.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05801237
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
- Sponsor: Shanghai HyaMab Biotech Co.,Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT05801237: https://clinicaltrials.gov/study/NCT05801237

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct05801237.json